New Grants

The Cardiovascular Disease and Diabetes Drugs and Devices grant provides organisations with funding for partnering with small to medium enterprises (SMEs) to accelerate into practice promising drugs and devices focused on cardiovascular disease and the complications of diabetes (types 1 and 2).

Deadlines and Timings

Applications are open and will close on 21 February 2024 at 5:00pm AEDT.

Overview and Grant Amount

The 2023 Targeted Translation Research Accelerator — Cardiovascular Disease and Diabetes Drugs and Devices Grant Opportunity is part of the MRFF and the Preventive and Public Health Research Initiative. It will support Australian medical research and medical innovation projects that, through competitively selected national organisation/s partnering with small to medium enterprises (SMEs), accelerate into practice promising drugs and devices focused on cardiovascular disease and the complications of diabetes (types 1 and 2).

The successful independent organisation/s will be responsible for ensuring that the funding by each organisation:

  • targets investment and related support through partnership projects to accelerate promising drug (topic A) or device (topic B) development projects
  • promotes commercialisation of novel drugs and devices for cardiovascular disease and for complications of diabetes (types 1 and 2)
  • provides a maximum of $1.5 million for each promising drug/device project
  • leverages support (including co-funding) from partner organisations such as industry
  • provides a minimum investment of $3 million into each of the following: cardiovascular disease; the disease-related complications in people with type 1 diabetes; and the disease-related complications in people with type 2 diabetes

A grant of up to $15 million for topic A and $13.5 million for topic B, to cover up to 100% of eligible expenditure.

For this grant opportunity, up to $28.5 million is available over 4 years from 2023-24 as follows:

  • Topic A (Aim 3 of Research Plan; Targeted Call for Research): drugs (preclinical and clinical development)
    • $4.0 million in 2023-24
    • $6.5 million in 2024-25
    • $2.0 million in 2025-26
    • $2.5 million in 2026-27
  • Topic B (Aim 3 of Research Plan; Targeted Call for Research): devices (including, but not restricted to, diagnostics)
    • $4.0 million in 2023-24
    • $6.0 million in 2024-25
    • $2.0 million in 2025-26
    • $1.5 million in 2026-27

Grant funds will be provided according to the funding profile indicated above; however, grant funds can be expended across the life of the project (project period).

Eligibility and Criteria

To be eligible, applicants must:

  • have an Australian Business Number (ABN)
  • be incorporated in Australia
  • be a medical research institute, a university, a corporate Commonwealth entity, a corporation (including businesses and not for profits)

Joint applications are encouraged, provided you have a lead organisation who is the main driver of the project and is eligible to apply.

Eligible Activities

To be eligible your project must:

  • establishment and support of a selection panel
  • undertaking a selection process
  • allocation of funds to selected, partnered SMEs
  • managing and reporting on outcomes, including activities of the SMEs
  • mentoring and networking activities to assist the selected SMEs
  • publicity and marketing
  • development/installation of research equipment
  • employment of personnel
  • other direct research costs

Eligible expenditure must be a direct cost of the project and must be incurred by you for required project audit activities. You must incur the project expenditure between the project start and end dates (activity start and completion dates) for it to be eligible unless stated otherwise.

Applicants are encouraged to thoroughly read the program guidelines set by the funding grant. Submissions must be lodged through the program online portal.

Expert Assistance

We have over 16 years of experience preparing EMDG and R&D tax incentive claims and can assist in making sure you receive your maximum rebate.

Working with us means you get the maximum grant with minimum risk and effort. Our expertise includes R&D Tax Incentive registration and tax schedules, Export Grants, Capital Expenditure and Infrastructure Grants.

Get in touch with us and let’s discuss this more in detail.

For information about other Australian Government Grants, visit Treadstone New Grants page and sign up to our newsletter!

error: Content is protected !!